Skip to main
COGT

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences is currently valued at $9.3B due to its positive outlook as a company. With a 90% probability of approval for bezuclastinib in advanced systemic mastocytosis, a 95% POA in non-advanced systemic mastocytosis, and a 90%POA in the 2L GIST indication, this shows strong potential for success in the biotechnology market. However, there are risks that must be considered, such as negative clinical data, setbacks in later-stage trials, failure to obtain regulatory approvals, and lower than projected commercial success.

Bears say

Cogent Biosciences is expected to submit an NDA for its lead program bezuclastinib, a precision therapy for systemic mastocytosis and GIST, in the coming months. FDA's Real-Time Oncology Review program may expedite this process, potentially leading to an approval in 2026. However, potential risks include unsuccessful clinical results, competition from other treatments, and regulatory or commercial challenges. With a strong balance sheet and multiple programs in its pipeline, COGT may be a good long-term investment opportunity for buyers looking to capitalize on its potential success in the precision therapy market.

COGT has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 11 analysts, COGT has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.